Ocugen Announces Data And Safety Monitoring Board Has Recommended To Proceed With Dosing Subsequent GA Subjects With Low Dose Of OCU410 In Dose-Expansion Phase And Concurrently Initiate Phase 2 Dosing
Ocugen Announces Data And Safety Monitoring Board Has Recommended To Proceed With Dosing Subsequent GA Subjects With Low Dose Of OCU410 In Dose-Expansion Phase And Concurrently Initiate Phase 2 Dosing
Ocugen 宣佈數據和安全監測委員會已建議在劑量擴展階段繼續給隨後 GA 受試者給藥低劑量 OCU410，同時開始第 2 階段給藥
Ocugen Announces Data And Safety Monitoring Board Has Recommended To Proceed With Dosing Subsequent GA Subjects With Low Dose Of OCU410 In Dose-Expansion Phase And Concurrently Initiate Phase 2 Dosing
Ocugen 宣佈數據和安全監測委員會已建議在劑量擴展階段繼續給隨後 GA 受試者給藥低劑量 OCU410，同時開始第 2 階段給藥
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。